Consensus Corbus Pharmaceuticals Holdings, Inc.

Stocks

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-10 EDT			5-day change	1st Jan Change
8.240 ^USD	-7.00%		-28.10%	+1.23%

08-13	Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating	MT
08-07	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating	MT

Evolution of the Average Target: Corbus Pharmaceuticals Holdings, Inc.

Evolution of the Target Price: Corbus Pharmaceuticals Holdings, Inc.

Changes in Analyst Recommendations: Corbus Pharmaceuticals Holdings, Inc.

d06b122b892.KsW1R9n7qXxGvrgNjmxGpoJlOQi1Vyg10b7MNRIGAkQ.S_f6f52-wBQr--ti-xYKxdYwTkSGMGBAuOH5ZFV8YDB79uculZ3tLgDT6Q~94d3b9098dc06fe1873e705339a10c7a

Analysts' recommendations: Corbus Pharmaceuticals Holdings, Inc.

08-13	Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating	MT
08-07	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating	MT
06-23	Mizuho Securities Cuts Price Target on Corbus Pharmaceuticals to $34 From $44, Maintains Outperform Rating	MT
06-17	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating	MT
05-22	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $44 From $40, Maintains Outperform Rating	MT
05-13	Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating	MT
04-29	Mizuho Keept Price Target on Corbus Pharmaceuticals to $40, Maintains Outperform Rating	MT
04-29	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $40 From $39, Maintains Outperform Rating	MT
04-29	Guggenheim Initiates Corbus Pharmaceuticals at Buy With $45 Price Target	MT
04-02	Mizuho Lifts Price Target on Corbus Pharmaceuticals Holdings to $40 From $39, Keeps Outperform Rating	MT
11-13	RBC Trims Price Target on Corbus Pharmaceuticals Holdings to $53 From $55, Keeps Outperform, Speculative Risk	MT
25-10-20	Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating	MT
25-10-18	Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25	CI
25-10-14	Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025	CI
25-05-20	Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating	MT
25-05-20	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating	MT
25-05-07	RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk	MT
25-02-28	William Blair Initiates Corbus Pharmaceuticals at Outperform	MT
24-09-24	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating	MT
24-09-23	B. Riley Cuts Price Target on Corbus Pharmaceuticals Holdings to $40 From $85, Keeps Buy Rating	MT
24-09-20	Top Midday Decliners	MT
24-09-20	Wedbush Cuts Corbus Pharmaceuticals Price Target to $51 From $85, Maintains Outperform Rating; Shares Tumble	MT
24-08-27	Mizuho Initiates Corbus Pharmaceuticals at Outperform With $74 Price Target	MT
24-08-07	Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $88 From $80, Maintains Outperform Rating	MT
24-07-30	Wedbush Initiates Corbus Pharmaceuticals at Outperform With $85 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CORBUS PHARMACEUTICALS HOLDINGS, INC.					+312.92%
	WUXI APPTEC CO., LTD.					+21.08%
	ARGENX SE					+17.64%
	INSMED INCORPORATED					+57.28%
	WUXI BIOLOGICS (CAYMAN) INC.					+22.33%
	BIONTECH SE					+23.63%
	GENMAB A/S					+17.8%
	PHARMAESSENTIA CORPORATION					+5.85%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+30.36%
	EXELIXIS, INC.					-6.52%
	Average					+50.24%
	Weighted average by Cap.					+22.35%